Chart-Typ:
Zeitraum:
| Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen | Anzeige / WerbungDie Biotechnologie entwickelt sich rasant weiter - und Unternehmen, die maschinelle Intelligenz mit medizinischem Know-how kombinieren, setzen sich durch.
Dieser Artikel... ► Artikel lesen |
| JNJ's IMAAVY Shows Positive Data In Indirect Treatment Comparison Among GMG Patients | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ), Monday announced new data regarding IMAAVY, an FcRn blocker, in adults with generalized myasthenia gravis or gMG.The data, taken from an indirect... ► Artikel lesen |
| Janssen-Cilag: DARZALEX Receives Positive CHMP Opinion | NEW BRUNSWICK (dpa-AFX) - Janssen-Cilag International NV, a Johnson & Johnson company, announced that the CHMP of the European Medicines Agency has recommended the approval of a new indication... ► Artikel lesen |
| Biogen Inc.: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy | Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically... ► Artikel lesen |
| Biogen Inc.: New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg... ► Artikel lesen |
| Biogen Inc.: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results | Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children... ► Artikel lesen |
| Ionis Pharmaceuticals, Inc.: Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. | - Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world - - Ionis will continue to independently commercialize TRYNGOLZA (olezarsen)... ► Artikel lesen |
| Ionis Pharma Reports Approval Of WAINZUA In The EU | LONDON (dpa-AFX) - Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca's WAINZUA has been approved in the European Union for the treatment of hereditary transthyretin-mediated... ► Artikel lesen |
| Ionis Pharmaceuticals, Inc.: WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy | - Second major approval for WAINZUA, which is marketed in the U.S. as WAINUA - - EU approval based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BG MEDICINE INC finden Sie auf Wallstreet Online.